title: Mechanistic studies on metabolic interactions between gemfibrozil and statins.
abstract: A series of studies were conducted to explore the mechanism of the pharmacokinetic interaction between simvastatin (SV) and gemfibrozil (GFZ) reported recently in human subjects. After administration of a single dose of SV (4 mg/kg p.o.) to dogs pretreated with GFZ (75 mg/kg p.o., twice daily for 5 days), there was an increase (approximately 4-fold) in systemic exposure to simvastatin hydroxy acid (SVA), but not to SV, similar to the observation in humans. GFZ pretreatment did not increase the ex vivo hydrolysis of SV to SVA in dog plasma. In dog and human liver microsomes, GFZ exerted a minimal inhibitory effect on CYP3A-mediated SVA oxidation, but did inhibit SVA glucuronidation. After i.v. administration of [(14)C]SVA to dogs, GFZ treatment significantly reduced (2-3-fold) the plasma clearance of SVA and the biliary excretion of SVA glucuronide (together with its cyclization product SV), but not the excretion of a major oxidative metabolite of SVA, consistent with the in vitro findings in dogs. Among six human UGT isozymes tested, UGT1A1 and 1A3 were capable of catalyzing the glucuronidation of both GFZ and SVA. Further studies conducted in human liver microsomes with atorvastatin (AVA) showed that, as with SVA, GFZ was a less potent inhibitor of the CYP3A4-mediated oxidation of this drug than its glucuronidation. However, with cerivastatin (CVA), the glucuronidation as well as the CYP2C8- and CYP3A4-mediated oxidation pathways were much more susceptible to inhibition by GFZ than was observed with SVA or AVA. Collectively, the results of these studies provide metabolic insight into the nature of drug-drug interaction between GFZ and statins, and a possible explanation for the enhanced susceptibility of CVA to interactions with GFZ.
authors.affiliation: Department of Drug Metabolism, WP75-100, Merck Research Laboratories, West Point, PA 19486, USA. thomayant_prueksaritanont@merck.com
authors.forename: Thomayant
authors.initials: T
authors.lastname: Prueksaritanont
authors.forename: Jamie J
authors.initials: JJ
authors.lastname: Zhao
authors.forename: Bennett
authors.initials: B
authors.lastname: Ma
authors.forename: Brad A
authors.initials: BA
authors.lastname: Roadcap
authors.forename: Cuyue
authors.initials: C
authors.lastname: Tang
authors.forename: Yue
authors.initials: Y
authors.lastname: Qiu
authors.forename: Lida
authors.initials: L
authors.lastname: Liu
authors.forename: Jiunn H
authors.initials: JH
authors.lastname: Lin
authors.forename: Paul G
authors.initials: PG
authors.lastname: Pearson
authors.forename: Thomas A
authors.initials: TA
authors.lastname: Baillie
mesh_terms: D000284:Administration, Oral; D000818:Animals; D019540:Area Under Curve; D002384:Catalysis; D004285:Dogs; D004347:Drug Interactions / Q000502:physiology; D015248:Gemfibrozil / Q000378:metabolism* / Q000494:pharmacology; D020719:Glucuronides / Q000378:metabolism; D014453:Glucuronosyltransferase / Q000378:metabolism; D006801:Humans; D006868:Hydrolysis; D000960:Hypolipidemic Agents / Q000097:blood / Q000737:chemistry / Q000378:metabolism* / Q000493:pharmacokinetics; D007527:Isoenzymes / Q000378:metabolism; D008862:Microsomes, Liver / Q000187:drug effects / Q000378:metabolism; D010084:Oxidation-Reduction / Q000187:drug effects; D019821:Simvastatin / Q000031:analogs & derivatives* / Q000097:blood / Q000737:chemistry / Q000378:metabolism* / Q000493:pharmacokinetics
chemical_list: D020719:Glucuronides; D000960:Hypolipidemic Agents; D007527:Isoenzymes; C063287:simvastatin acid; D019821:Simvastatin; D014453:Glucuronosyltransferase; D015248:Gemfibrozil